Topics

Adjust in time: Beware of the labelling challenges that Annex VI brings

05:02 EDT 7 Oct 2019 | Manufacturing Chemist

Gordon Alexander and Simon Jones from PRISYM ID outline how imminent changes to EU clinical trial regulations will have major implications for labelling processes.

Original Article: Adjust in time: Beware of the labelling challenges that Annex VI brings

NEXT ARTICLE

More From BioPortfolio on "Adjust in time: Beware of the labelling challenges that Annex VI brings"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...